Li Yu, Chang Jianying, Jiang Tiejian
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008; Department of Endocrinology, Yongzhou Central Hospital, Yongzhou Hunan 425000, China.
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Aug 28;42(8):947-952. doi: 10.11817/j.issn.1672-7347.2017.08.012.
To investigate relationships between serum chemerin and bone mineral density (BMD) in patients with newly diagnosed Graves disease (GD). Methods: A total of 120 newly diagnosed GD patients with a course more than 3 months were enrolled from the Department of Endocrinology between June 2013 and June 2015. Sixty age- and sex-matched healthy people served as a normal control. Serum levels of chemerin, β-crosslaps (β-CTX), and N-MID-osteocalcin (N-MID-OT) were measured by ELISA. Fat mass and BMD were evaluated by dual energy X-ray absorptiometry (DEXA). Results: Compared with the normal control, the fat mass, lean weight, fat mass index (FMI) and body mass index (BMI) in the GD group were decreased, and BMD in all skeletal sites was decreased. There was a positive correlation between them (all P<0.05). Serum level of chemerin was increased and it was positively correlated with β-CTX or N-MID-OT level and negatively correlated with fat mass, FMI or BMI in the GD group. There was a negative correlation between chemerin level and BMD in femoral neck, total hip, lumbar or right forearm distal 1/3 (rs=-0.352, -0.279, -0.379, -0.289, -0.394; P<0.05). After adjusting for age, fat mass or BMI, the correlation of chemerin with total hip or bone mineral density remained significant (rs=-0.273, -0.378; P<0.05). Multiple linear regression analysis revealed that chemerin or BMI was correlated with BMD (P<0.05). Conclusion: The decrease of bone mineral density in patients with GD is not only related to the direct or indirect effect of excessive thyroid hormones on systemic and osteoblastic cells, but it is also related to the negative regulation of bone metabolism due to the elevated chemerin level.
探讨初诊格雷夫斯病（GD）患者血清趋化素与骨密度（BMD）之间的关系。方法：选取2013年6月至2015年6月内分泌科收治的120例病程超过3个月的初诊GD患者。60例年龄和性别匹配的健康人作为正常对照。采用酶联免疫吸附测定法（ELISA）检测血清趋化素、β-交联羧基末端肽（β-CTX）和N-端中段骨钙素（N-MID-OT）水平。采用双能X线吸收法（DEXA）评估脂肪量和骨密度。结果：与正常对照相比，GD组的脂肪量、瘦体重、脂肪量指数（FMI）和体重指数（BMI）降低，所有骨骼部位的骨密度均降低。它们之间存在正相关（均P<0.05）。GD组血清趋化素水平升高，且与β-CTX或N-MID-OT水平呈正相关，与脂肪量、FMI或BMI呈负相关。趋化素水平与股骨颈、全髋、腰椎或右前臂远端1/3的骨密度呈负相关（rs=-0.352、-0.279、-0.379、-0.289、-0.394；P<0.05）。校正年龄、脂肪量或BMI后，趋化素与全髋或骨密度的相关性仍然显著（rs=-0.273、-0.378；P<0.05）。多元线性回归分析显示，趋化素或BMI与骨密度相关（P<0.05）。结论：GD患者骨密度降低不仅与甲状腺激素过多对全身及成骨细胞的直接或间接作用有关，还与趋化素水平升高对骨代谢的负调节有关。
